Loxo Oncology Inc. (LOXO)

234.76
0.03 0.01
NASDAQ : Health Technology
Prev Close 234.73
Open 234.70
Day Low/High 234.66 / 234.88
52 Wk Low/High 103.50 / 234.93
Volume 783.31K
Avg Volume 939.00K
Exchange NASDAQ
Shares Outstanding 30.75M
Market Cap 7.22B
EPS -5.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Stocks End Lower as Wall Street Gets No Boost From State of the Union

Stocks End Lower as Wall Street Gets No Boost From State of the Union

Stocks ended lower Wednesday as investors found little in Donald Trump's State of the Union address to warrant extending recent market gains.

Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.

Donald Trump, China Trade, Disney, Snap and GM - 5 Things You Must Know

Donald Trump, China Trade, Disney, Snap and GM - 5 Things You Must Know

U.S. stock futures mixed as investors remain worried the U.S. and China could fail to reach a trade agreement following Donald Trump's State of the Union address; Walt Disney rises as earnings beat estimates but expenses could rise from the company's new digital offerings; Snap soars as losses narrow and its user growth stabilizes.

2 Small-Cap Biotech Stocks That Are on My Radar

2 Small-Cap Biotech Stocks That Are on My Radar

These high risk/high reward oncology names look significantly undervalued, right now.

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

These themes are working despite the turmoil in Washington and slowing global growth.

These 2 Biotech Stocks Seem Significantly Undervalued

These 2 Biotech Stocks Seem Significantly Undervalued

I would add to them on any significant dips in the market.

Banks Are Leading: Cramer's 'Mad Money' Recap (Wednesday 1/16/19)

Banks Are Leading: Cramer's 'Mad Money' Recap (Wednesday 1/16/19)

Jim Cramer looks at the run in the financial stocks and says banks are leading this market back.

Jim Cramer: There's a Ton More Deals in the Pipe

Jim Cramer: There's a Ton More Deals in the Pipe

Deals that simply were unworkable four months ago because of price are now being done with alacrity.

The Gold Rush of 2019

The Gold Rush of 2019

Newmont Mining will acquire Goldcorp in a $10 billion deal, and here's how I'd trade Newmont.

INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Recently Announced Merger

INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Recently Announced Merger

NEW YORK, Jan. 13, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: MINDBODY, Inc.

Pfizer and the Urge to Merge

Pfizer and the Urge to Merge

My stated reason for being in Pfizer all along has been price stability and income.

Some Early 2019 Market Observations

Some Early 2019 Market Observations

I would not be surprised if we see a bout of profit-taking in the near future given the sharpness of the recent rebound.

This Market May Just Be in an Uptrend: Market Recon

This Market May Just Be in an Uptrend: Market Recon

This is the kind of reversal that happens in a bull market.

2 Small-Caps That Should Continue to Stage Comebacks in 2019

2 Small-Caps That Should Continue to Stage Comebacks in 2019

Beaten-down Entercom Communications and Dynavax Technologies are off to good starts this year and should continue to improve.

WEISSLAW LLP: Loxo Oncology, Inc. Acquisition May Not Be In The Best Interests Of LOXO Shareholders

WEISSLAW LLP: Loxo Oncology, Inc. Acquisition May Not Be In The Best Interests Of LOXO Shareholders

NEW YORK, Jan. 8, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Loxo Oncology, Inc.

In Case You Missed it: M&A Is Hot to Start January, GE Could Fetch $40 Billion

In Case You Missed it: M&A Is Hot to Start January, GE Could Fetch $40 Billion

Could there be more M&A this year than Wall Street had thought? Also, GE's quest for more liquidity took another baby step Monday.

Hunt for Winning Stocks: Cramer's 'Mad Money' Recap (Monday 1/7/19)

Hunt for Winning Stocks: Cramer's 'Mad Money' Recap (Monday 1/7/19)

Jim Cramer says companies that innovate become market-leading stocks, and can create tremendous wealth.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Loxo Oncology, Inc.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Loxo Oncology, Inc.

NEW YORK, Jan. 7, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Loxo Oncology, Inc.

3 Things to Know at Market Close: Tesla Grows In China, Pharma Binds, GE Unwinds

3 Things to Know at Market Close: Tesla Grows In China, Pharma Binds, GE Unwinds

Tesla, the big pharma mergers and General Electric are some of the top stories on TheStreet.

Luxoft Soars After Announcing $2 Billion Deal to Be Bought by DXC Technology

Luxoft Soars After Announcing $2 Billion Deal to Be Bought by DXC Technology

Luxoft is to be bought for about $2 billion by DXC Technology.

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

The Dow Jones Industrial Average is higher Monday amid improved prospects for a trade deal between the U.S. and China.

Celgene Expects to Generate Up to $17.2 Billion in Revenue in 2019

Celgene Expects to Generate Up to $17.2 Billion in Revenue in 2019

The company expects revenue to jump 12% year over year.

Eli Lilly to Buy Loxo Oncology for $8 Billion in Second Major 2019 Drug Takeover

Eli Lilly to Buy Loxo Oncology for $8 Billion in Second Major 2019 Drug Takeover

Eli Lilly & Co. says Monday it will pay $8 billion in cash for cancer drug specialists Loxo Oncology in the second major pharmaceutical sector deal of the year.

US Futures Flat, Europe Slides, as Fed Rally Fades Despite Trade Talk Progress

US Futures Flat, Europe Slides, as Fed Rally Fades Despite Trade Talk Progress

Global stocks traded higher Monday, following on from Friday's spectacular rally on Wall Street, as investors cheered much stronger-than-expected U.S. jobs data paired with twin dovish messages from the Federal Reserve and the People's Bank of China that look to support beaten-down asset prices heading into the fourth quarter earnings season.

Jim Cramer: These Pharma Deals Are Game Changers

Jim Cramer: These Pharma Deals Are Game Changers

Pharma companies that have cash are looking at what has happened to this stock market and buying.